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Abstract 
  This dissertation was written as a part of my MSc in Bioeconomy: Biotechnology and 
Law at the International Hellenic University. 
  The first section of this study deals with the applications of microalgae in the 
pharmaceutical sector. Eukaryotic microalgae are photoautotrophic micro-organisms 
and constitute the foundation of most aquatic environments due to their rich 
biodiversity and possibly high growth efficiency; nevertheless, they represent a vast and 
underexplored bioresource. About the safety and the prevention of diseases, 
microalgae have been reported as potential sources of new natural antimicrobials. Such 
species develop various secondary bioactive metabolites with antibacterial activities 
such as free saturated or unsaturated fatty acids, carbohydrates, proteins, and lipids, 
and work is underway to find natural molecules to restrict the misuse of industrial 
antibiotics. Therefore, microalgae consist of one major promising commercial 
opportunity for these substances in the field of pharmaceuticals, antibiotics, anticancer, 
antibacterial, antiviral, anti-fungal functions, and the treatment of other human 
diseases. 
  The second part includes a SWOT analysis of a start-up pharmaceutical company using 
microalgae, with emphasis on European regulations for new bioproducts, as well as 
initiatives for public and private funding. The pharmaceutical industry has had an 
accelerating rate of costs increase in new drug production while the number of new 
drugs authorized and released in the market has been very small due to increased 
public regulation. Partnership with the biotechnology industry is one of the key choices 
to improve this situation. If the pharmaceutical industry succeeds in addressing the 
issues responsible for high cost in the sector with a new marketing strategy, it might 
prove very beneficial for both of them as a partner of the biotechnology industry. 
Finally, this sustainable business model for a start-up pharmaceutical company is 
recommended in accordance with European strategies for a sustainable Bioeconomy. 
 
Keywords: Microalgae; Pharmaceutical applications; European regulations; Business 
model 
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1. Introduction 
1.1. General Characteristics of Microalgae 
  Certainly, “our life depends on microalgae” since they compose 50 percent of overall 
oxygen production (Chapman, 2013). As autotrophs support aquatic ecosystems, and in 
general all land plants and animals lean on microalgae directly or indirectly. Firstly, the 
primary production of marine and freshwater bodies relies on microalgae (Borowitzka 
et al, 2016). Secondly, they are situated in the base of food chains having an essential 
role in the world’s aquaculture industries for their protein needs (Griffiths, 2013). 
  Based on the size and morphology, algae may be subdivided into 2 main categories: 
macroalgae and microalgae. Macroalgae are composed of multiple cells, organized into 
structures that resemble higher plant roots, stems, and leaves (e.g. kelp). Microalgae 
are mostly unicellular, a diverse group of primary producers (autotrophs) organisms 
capable of forming organic compounds from pure inorganic materials like atmospheric 
or marine carbon dioxide (Sigamari et al, 2016). They are microscopic in comparison to 
algae which are simpler autotrophic organisms with a large variety (Ranganathan and 
Yaakob, 2013). Today's advanced plant life is believed to have been developed from 
these basic plant-like microscopic organisms (Mutanda, 2013). 
  Around 41,000 species of macroalgae and microalgae were described. The 
microalgae are categorized according to the quality of photosynthetic pigments, the 
food reserve for carbohydrates, the cell walls, the structure and orientation of flagella 
1(Levine and Fleurence, 2018). Also, the microalgae are described in the generally 
accepted algae phyla (divisions), meaning: 
                                                          1 A flagellum (plural: flagella) is a long, whip-like structure which allows to move certain single organisms 
https://simple.wikipedia.org/wiki/Flagellum. 
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Figure 1. Microalgae Divisions. Modified from: Griffiths, 2013. 
 
  Prokaryotic cyanobacteria are often included in this term as well, but some scientists 
exclude the prokaryotic blue-green algae (=cyanobacteria) and limit the definition of 
microalgae to include solely eukaryotic cells (Stanier et al., 1971). This thesis is 
restricted to eukaryotic microalgae only.  
1.2. Microalgae as Organisms with Particular Biotechnological Interest 
  There are several reasons why interest in microalgae growth is now thriving globally. 
Micro-algae are not particularly complex micro-organisms and are present in almost all 
earth's habitats from the sea, freshwater, desert sands, and hot springs, to snow and 
ice (Williams & Laurens, 2010). These many different environmental niches are, 
planktonic, benthic (sand, water, soil), epilithic, epiphytic, (symbiosis with the fungus 
and invertebrates), aquatic and in rare occasions parasitic relationships. Other classes 
of microalgae may form biofilms, colonial structures, mats and grasses.  
Although the total amount of microalgae listed is vast, only a few dozen are genuinely 
elucidated in their nutritional, environmental, pathogenic or business potential (Levine 
and Fleurence, 2018). Additionally, only a small percentage, i.e. approximately 20 
microalgae, are used economically (Posten and Chen, 2016). 
  Furthermore, these microalgae contain proteins, pigments, essential fatty acids, 
vitamins, polysaccharides and minerals (Parsaeimehr, 2017). Such high-value products 
Microalgae Divisions (phyla)  
Chlorophyta (green 
algae)  
Chrysophyta  
Cryptophyta  
Dinophyta 
(dinoflagellates)  
Haptophyta 
(coccolithophorids)  
Euglenophyta 
(euglenoids)  
Glaucophyta  Rhodophyta (red algae)  
ochrophyta (diatoms of bacillariophyta)  
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may be proven particularly important and beneficial to the pharmaceutical industry by 
giving new choices to treat illnesses like inflammation and immunomodulating actions 
(Ahmadi et al, 2015). Eventually, the microalgae that provide us with oxygen, foods, 
and car fuel, also provide us with effective medical substances against virus diseases 
(Herpes simplex and AIDS), cancer and drug-resisting bacterial strains. Pharmaceutical 
products of quality and their industrial marketing are still developed and can be viewed 
as a key to a multimillion-dollar industry. Scientists have just begun to explore the huge 
biological resource and physiological perspective of microalgal species as growing in 
every environmental niche (Bhattacharjee, 2016). 
  The evolution of algae over 2,500 million years, its abundance and ability to 
withstand extreme environments have contributed to novel strategies of protection, 
interaction, and survival, leading to their human drug and nutraceutical potential. 
Nevertheless, one cautionary note is that the discovery of drugs in microalgae depends 
on environmental regimes that induce metabolic plasticity (Lauritano et al., 2016). The 
rates of metabolites and bioactivity depend on habitat and seasonal conditions. 
Production and concentration of primary and secondary metabolites are based on a 
process of development (Vidoudez and Pohner, 2012), different clones (Gerecht et al., 
2011), kind of light (Depauw et al., 2012), control of temperature (Huseby et al., 2013), 
media for seed (Alkhamis and Qin, 2015), weeding control procedure (Pohnert, 2002), a 
technique for extraction (Juttner, 2001) and various elements (Chen et al., 2011). 
  The nutritional needs of some microalgal strains are recognized and microalgal 
growing technology is evolving quickly. Also, the development of protocols in genetic 
engineering has brought new approaches to molecular algal systems. The general study 
recently carried out in genomics and molecular biology methods of microalgae have 
achieved remarkable dimensions, with huge numbers of undiscovered algae strains 
from extreme environments (Brodie and Lewis, 2007).  
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1.3. Macromolecules of microalgae useful for pharmaceutical applications  
  A large quantity of various components is produced by microalgae, such as: 
Lipids  
  Microalgae contain a large number of lipids, around 30–50% of their total weight. In 
comparison to other lipid-based crops, microalgae lipids can assemble a higher 
percentage which makes them more appealing to produce biodiesel and health food 
supplements (Yeh and Chang, 2012). 
 
Proteins  
  Proteins are part of the main components of microalgae, representing between 50 
and 70% of their composition. Besides, protein is can be consumed by humans or 
animals (Chew et al., 2017). Even though some microalgae comprise toxic proteins, 
testing can be carried out to discover the safe proteins for use.  
 
Carbohydrates  
  Microalgae usually have a high carbohydrate amount that is around 50% greater 
than their dry weight because they have good effectiveness in photo-conversion and 
easy storage of carbohydrates (Yen et al., 2013). Algal carbohydrates are composed 
mainly of glucose, starch, cellulose, and polysaccharide of several kinds. Microalgae 
polysaccharides can regulate the immune system and inflammatory reactions, and 
produce cosmetic chemicals, food ingredients, and natural therapeutic agents.  
 
Pigments  
  It is important to highlight three basic natural pigment classes in microalgae: 
carotenoids, chlorophyll, and phycobiliproteins. These pigments were used as vitamins 
in food and feed, additives, cosmetics, pharmaceutical industries, agents to color food 
and biomaterials (Nobre et al., 2013; Tamiaki et al., 2014, Zhou et al, 2015). First of all, 
carotenoids are fat-soluble coloring agents, which dye plants, and secondly 
chlorophylls are lipid-soluble pigments existing in vegetables and fruit during 
photosynthesis. Another carotenoid from microalgae is astaxanthin, an important 
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antioxidant agent, as carotenoids have strong anti-aging, sun protection, and anti-
inflammatory impact in the immune system (Cheng et al., 2016). 
 
Vitamins  
  Compared with common food, microalgae have high levels of vital vitamins, like 
riboflavin a very important vitamin for maricultured animals (Brown and Farmer, 1994). 
Also, more studies must be performed to test the safety of these vitamins after 
consumption (Bonnet et al., 2010).  
 
Polyunsaturated fatty acids  
  Polyunsaturated fatty acids (PUFA) are commonly known as important food 
elements that help prevent multiple cardiovascular diseases. The fast diminution of 
marine resources has hampered the acquisition of these ingredients from ocean fish, 
where augmented PUFAs demand has been responsible for the revealing of substitute 
sources for EPA and DHA (fatty acids). Microalgae can produce PUFAs that are 
important to human health and nutrition (Wang et al., 2015b).  
These previous components may have different applications as table 1 demonstrates. 
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Table 1. Potential uses for bioproducts obtained from microalgal biorefineries. 
Modified from: Chew et al., 2017. 
Activity Application 
Nutraceutical, antimicrobial, anti-
inflammatory 
Nutritional supplement, 
antiproliferative, capacity to resist 
infections and diseases 
Antioxidant, natural pigment Supplement and food ingredient for 
humans, feeding of fish and shellfish  
Biofuels  Fermentation of natural gas via 
biomass  
digestion to produce biodiesel 
 
Fertilizers Utilization of biomass in arable land for 
production of nitrogen and phosphorus 
High-value molecules  
 
Chlorophyll-a, phycocyanin, b-carotene, 
γ-linolenic acid, eicosapentaenoic acid, 
and stable biochemical isotopes  
 
Anticancer and antitumor Antiproliferative. Inducing G1 inhibition 
in post-gastric carcinoma cells  
Chemical industry Evaporative organic compounds  
 
 
 
1.4. Aim of the study 
  The current study΄s aim is to discuss on a global scale the latest developments in 
pharmaceutical research with the use of microalgae and to highlight the recent 
discoveries in the field. 
   The study's first section attempts more explicitly to summarize their potential 
pharmaceutical innovations in international literature as well as the different 
applications in the areas of human health. This section discusses the understanding of 
the microalgae as the origin and ingredients in bioactive molecules, i.e. in cancer 
treatment, metabolism, oxidative stress, inflammation, immunology, cardiovascular-
renal-respiratory-hepatology-dermatology-neuroscience-ophthalmology, and rare 
diseases and accidents which consist of basic domains in the pharma industry (www. 
novartis.com). 
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  The second section includes the regulations and the restrictions as far as the 
pharmaceutical use of microalgae is concerned. An attempt to link the pharmaceutical 
uses of microalgae with the concepts of Bioeconomy, circular economy, and 
sustainability on the European Union level was made. In this chapter also, a swot 
analysis of a start-up biotechnological company using microalgae is presented. Swot 
analysis is essential to coordinate the different departments of the company by 
defining the internal planned factors-strengths and weaknesses, and the external 
planned factors-opportunities and threats. With the practical application of the above 
principles, a sustainable business model is introduced which illustrates the high level of 
applicability and inclusion into the EU project. 
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2. Methodology  
  The Elsevier Scopus and ScienceDirect databases simultaneously with Google 
Scholar and PubMed were thoroughly searched by applying the following keywords 
[pharmaceutical uses of microalgae, anticancer-antiviral-antibacterial – antifungal – 
cardiovascular – renal – metabolism – respiratory – inflammation – immunology – 
hepatology – dermatology – neuroscience -ophthalmology – rare diseases – wounds 
(alone or in combination with microalgae)] in the "Article title, abstract, keywords" 
section in Scopus of ScienceDirect, without any constraint of the date or report form. 
From 1960 to 2019 the search provided thousands of documents. The findings have 
been categorized and checked, excluding those that did not match the study criteria. 
2.1. Results 
  This research reveals the augmentation of publications about the pharmaceutical 
use of microalgae during the last 3 decades, as demonstrated in Fig.2, which follows 
the growth of technologically advanced equipment and the marketing of microalgae-
based products. Especially the last decade from 2010 until 2019 the rise of publications 
is spectacular: 
 
Figure 2: Graphical representation of researches on microalgae pharmaceuticals from 1990 to 
2019. 
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  As far as pharmaceutical uses of microalgae are concerned, we ascertain that the publications about anticancer, antiviral, antibacterial, and 
antifungal drugs from microalgae have risen especially since 2010. This is due to the growing interest in finding new substances that will defeat 
various diseases. In graph 1, we observe that microalgae substances for metabolism show a big development. Moreover, pharmaceutical use of 
microalgae in cardiovascular, dermatology, inflammation, and neuroscience present also, a significant rise during the last decade. On the other 
hand, renal and respiratory drugs for microalgae have not been studied satisfactorily yet, as well as hepatology drugs. Finally, microalgae 
research for accident wounds augments especially the last years, while publications for ophthalmology and rare diseases are also limited. 
 
 
Graph 1: Publications on microalgae per human diseases from 1990 to 2019. 
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  On figures below, we see the top 15 countries in microalgae biotechnology and 
research such as United States, Russia, Iran, China, Japan, Germany, India, France, 
Canada, Australia, Brazil, Spain, Algeria, United Kingdom, South Korea. The United 
States, Russia, and China are the three leading counties in publications. 
 
 
Figure 3: World map with main countries and their number of scientific publications on 
microalgae. The red-orange color indicates a greater number of publications, the blue-green color 
indicates the smaller, and white when it does not exist. Modified by Garrido-Gardenas et al., 
2018. 
 
 
Figure 4: Graph on publications concerning the use of microalgae in pharmaceuticals per country. 
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3. Pharmaceutical uses of microalgae  
  Physicochemical and pharmacological studies have given particular attention to 
extracting and generating new bioactive metabolites for therapeutic purposes from 
marine micro-algae. On the other hand, microalgae are a healthy source of human 
dietary due to macro and micronutrients. These bioactive molecules may have the 
ability to improve human health (Nazih and Bard, 2018).  Hence, microalgae can be 
utilized as a functional food (supplements) as well as pharmaceutical.  
  In this coursework, eukaryotic microalgae products are discussed in terms of 
pharmaceutical use together with their use as functional food (nutraceuticals). 
3.1. Anticancer activity  
  In 2015, cancer, worldwide the second most important cause of death, killed 8.8 
million people, mainly: Cancer of the liver (788,000 deaths); cancer of the colon 
(774,000 deaths); cancer of the stomach (754,000 deaths); cancer of the breast 
(571,000 deaths) (OMS data). It is predicted that the number of new cases will increase 
by 70% over the next two decades. Also, the increasing economic effect of cancer is 
significant: in 2010, the total costs per year of the disease were projected to be around 
US$ 1160 billion (US$) (Dewi et al., 2018).  
  Cancer is the failure or dysfunction of precisely regulated processes of a cell, such as 
a cell division, proliferation, and programmed cell deaths (apoptosis), as well as the 
mechanisms of controlled feedback (Klaunig and Kamendulis 2004). This contributes to 
the rapid growth and metastases of the cancer cell (Abel et al. 2014). 
  Chemotherapy, one of the key therapies currently available, has little efficacy by some 
life-threatening negative results and the formation of therapeutic resistant cell lines. The 
use of natural products in the therapy of various diseases consists of a significant field of 
research for new drugs. Microalgae can generate biologically active molecules for the 
pharmaceutical industry because they can be conveniently grown, short-produced, and 
environmentally friendly. The majority of published research on anticancer properties 
from microalgal strains studied pure ingredients rather than extracts to diminish the 
danger of patient side effects (Dewi et al., 2018). Bioactive microalgae molecules with 
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anticancer applications are carotenoids, glycolipids, polysaccharides, and proteins (Talero 
et al., 2015).  
 
Carotenoids and Cancer 
  Five carotenoids with important anti-cancer activities are reported: β-carotene, 
lutein, astaxanthin, violaxanthin, and fucoxanthin. Since the majority of organisms 
cannot generate these compounds, they depend on nutrition as a source.   
β-carotene 
  Microalgae are a rich carotenoid origin (Varela et al., 2015), with Dunaliella for β-
carotene and Haematococcus for astaxanthin being the major generators. Palozza et al. 
(2005) therefore, found out that the development of human colon cancer cell lines was 
significantly limited by β-carotene pigments.  
 
Astaxanthin 
  Haematococcus pluvialis, Chlorella zofingiensis, and Chlorococcum sp. are the major 
microalgal sources of astaxanthin (Liu et al., 2014). Palozza et al. (2009) have 
investigated the impact of astaxanthin on the development of cell lines and have 
demonstrated the ability of this carotenoid to impede the proliferation of human CRC 
(colorectal cancer) cell lines. Nonetheless, no astaxanthin clinical trials have been 
published yet. The strong association between astaxanthin concentrations and 
antiproliferative impact on the lines of hepatoma, breast, and pulmonary cancer has 
been stated by Song et al. (2011). 
Zhang et al. (2011) found that astaxanthin was the most powerful of the four types of 
carotenoids to impede cell proliferation. Some studies have documented the impact of 
astaxanthin on apoptosis (programmed cell death). Astaxanthin from microalgae 
should, therefore, be a perfect candidate, not only for the control of cancer but also as 
a chemotherapy tool. However, to prove this hypothesis, clinical research is required 
(Nazih and Bard, 2018). 
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Lutein 
  An inverse connection between nutritional carotenoid, particularly lutein intake, and 
various types of cancers (colon, lung, breast ) is generally proven (Dorgan et al., 1998). 
Lutein is primarily developed by Dunaliella salina (Fu et al., 2013), Chlorella sorokinian 
(Pasquet et al., 2011) and Chlorella prothelkoides (Shi and Chen, 2002), and has anti-
proliferative impact on human colon cell line HCT-116 (Cha et al., 2008). Also, low 
levels of dietary lutein (0.002% and 0.02%) have been shown to prevent the occurrence 
and development of mammary tumors (Park et al., 1998). 
 
Violaxanthin 
  Violaxanthin isolated from D. salina (Pasquet et al., 2011) and Chlorella ellipsoidea 
(Talero et al., 2015) has antigrowth and proapoptotic effects against human colon 
cancer cell line HCT-116.  
 
Fucoxanthin 
  Fucoxanthin is the most promising carotenoid against cancer expansion. Their anti-
proliferative results on SK-hepatoma, BNL CL.2(embryonic liver) cells, cancer cells 
(Caco-2, HT29, and DLD-1), the cells of prostate cancer PC-3, and HL-60 leukemia, were 
described by Kumar and al. (2013). Fucoxanthin, therefore, is demonstrating great 
potential in cancer as a chemotherapeutic product. 
 
Lipids and Cancer 
  Human nutrition includes low amounts of a fatty acid group, ω-3 polyunsaturated 
fatty acids (ω-3 PUFAs), and high quantities of ω-6 PUFAs, which lead to cancer 
incidence. PUFAs and glycolipids are known to be effective anticancer factors by 
activating apoptosis and also by increasing the responsiveness of tumors to anticancer 
drugs (Nazih and Bard, 2018). Fish oils are the main sources of ω-3 PUFAs. Over the last 
years, microalgae have been turned into a good option for ω-3 PUFAs (DHA2, EPA3). 
The fact that the high consumption of ~ 3 PUFAs, mainly DHA and EPA, minimizes the                                                         2 Docosahexaenoic acid 3 Eicosapentaenoic acid  
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risk of breast, colon, prostate, pancreatic and endometrial cancer has been indicated 
by epidemiological studies (Arem et al., 2013).  
  A lot of in vitro studies have presented that DHA shows anticancer activity by 
provoking oxidative stress and oxidative DNA damages to cancer cells. Indeed, both 
EPA and DHA cause ROS (reactive oxygen species) concentration and caspase-84-
dependent apoptosis in breast cancer, pancreatic cancer (Fukui et al., 2013; Kang et al., 
2010), and prostate cancer cells. Clinical trials have also revealed that the efficiency of 
chemotherapy increases with ω 3-PUFAs, particularly DHA (Bougnoux et al., 2009).  
  Glycolipids, these variant lipids, are located at high amounts in thylakoid 
membranes of microalgae chloroplasts. Monogalactosyldiacylglycerol (MGDG) shrunk 
the HT-29 human colon adenocarcinoma tumors (Mizushina et al., 2012) and also 
digalactosyldiacylglycerol (DGDG) created apoptosis in Caco-2 colon cells (Hossain et 
al., 2005).  
 
Polysaccharides and Cancer 
  Diatoms, chlorophytes, prasinophytes, haptophytes, rhodophytes, and dinoflagellates 
(Raposo et al., 2015) produce a large number of polysaccharides. One important 
anticancer substance is GA3P (d-galactan sulfate, associated with l-(+)- lactic acid), an 
extracellular polysaccharide, refined from Gymnodinium sp., which hampered the 
proliferation of different cancer cell lines, especially some colon cancer cell lines 
(Umemura et al., 2003). It has been documented that the same polysaccharide induces 
apoptosis in lines of human leukemia (Sogawa et al., 1998). Homopolysaccharide from G. 
impudicum in vitro and in vivo, suppresses the development of tumor cells, activating the 
immune system. 
 
Proteins, Peptides, and Cancer  
  As far as proteinic substances are concerned, a large number of microalgae can 
produce therapeutic proteins and peptides (Talero et al., 2015). It has been reported 
that phycobiliproteins from red-algae Porphyridium sp. demonstrate anti-cancer,                                                         4 Caspase-8 is a cysteine proteases (proteins), which are involving in apoptosis and cytokine processing. 
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antioxidant and anti-inflammatory properties (Romay et al., 2003). Therefore, multiple 
microalgae have shown signs of anticancer peptides (Kang and Kim, 2013). 
  Among them, we can identify a polypeptide from Chlorella pyrenoidosa, Chlorella 
vulgaris (Wang and Zhang, 2013). Such compounds have expressed cytotoxic properties 
along with antimitotic or proapoptosis function and, in some cases, inhibitory impact 
on proteasome5. It can thus be proposed that proteins and peptides produced by 
microalgae can aid in preventing and/or treating human cancer. In vivo studies would, 
though, be necessary to bring valid conclusions, particularly on humans (Nazih and 
Bard, 2018). 
3.2. Antiviral activity 
  Unfortunately, there is no specific vaccine for many viral infections, some 
respiratory tract viruses, Herpes Simplex Viruses (HSV-1 and HSV-2), or dengue viruses. 
Also, drug resistance by multiple viruses such as HIV (Human Immunodeficiency Virus) 
type 1 or HSV-1 to usable antiviral agents has always been a significant barrier to the 
treatment of viral infections, prompting the search for new effective molecules 
(Ahmadi et al., 2015).  
  Therefore, methanolic or ethanolic extracts have been used to identify antiviral 
agents in microalgae for many years, with success rates in study and implementations 
(Lau et al., 1993; Ohta et al., 1998; Fabregas et al., 1999; Bergé et al., 1999; Abdo et al., 
2012; Sanmukh et al., 2014; Ahmadi et al., 2015). These various solvents isolate 
antiviral components with environmentally sustainable approaches. For example, 
Santoyo et al. (2010) examined the antiherpetic properties of Pressurized Liquid 
Extraction (PLE) extracts (hexane, ethanol, and water) from Haematococcus pluvialis 
and Dunaliella salina. Pretreatment of Vero cells with 75 μg/mL of H. pluvialis ethanol 
extract stopped virus infection by about 85%, whilst the same water and hexane 
extract levels diminished the virus infection by 75% and 50%, accordingly. The antiviral 
function of PLE water extracts was shown to interact with polysaccharide 
concentration; nevertheless, other components, particularly fatty acids, could be 
essential for this antiviral activity (Santoyo et al., 2012).                                                          5 Proteasome is an extensive protein complex that causes intracellular protein degradation 
 17 
 
Purified Molecules 
 Comparing certain types of molecules, lipids, proteins, or pigments, a broad 
spectrum of literature concerns antiviral algal polysaccharides. Ginsberg et al. (1947) 
and Gerber et al. (1958) first showed potential antiviral activity for algal 
polysaccharides, finding that polysaccharides isolated from macroalgae protected 
embryo eggs from influenza B and mump viruses. In general, polysaccharides are 
widely cited as having several benefits, such as reduced cost of production, a broad 
range of antiviral effects, low cytotoxicity, safety, and strong approval. But such 
complex molecules, together with the enzyme's failure to absorb them, aid in the 
body's cytotoxic results, which limits their clinical development. Recently, interest in 
microorganisms as sources of high molecular weight polysaccharides has grown, as 
these biopolymers often have advantages over the commonly produced 
polysaccharides (Dewi et al., 2018). 
  
Polysaccharides 
  As regards red macroalgae, extracellular polysaccharides were the focus of active 
research (Geresh et al., 1990, 2002a,b; Huleihel et al., 2001, 2002; Lupescu et al., 1991; 
Raposo et al., 2013, 2014a; Shrestha et al., 2004; You and Barnett, 2004). This table 
shows various purified polysaccharides of microalgae showing antiviral activities. 
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Table 2: Several purified polysaccharides of microalgae with antiviral activities:  
Modified by Dewi et al., 2018. 
Compounds Microorganisms Viruses References 
Rhodophyta    
Highly sulfated 
polysaccharide 
Porphyridium 
cruentum 
HSV-16, HSV-2, 
Vaccina 
Huang et al., (2005) 
Raposo et al., 
2014a,b 
Sulfated 
exopolysaccharide 
P. purpureum 
Porphyridium sp. 
Vaccina 
HSV-1, HSV-2 
 
Radonic et al., (2010) 
Sulfated 
polysaccharide 
Rhodella 
reticulata 
Varicella zoster 
virus7 
 
Huleihel et al., (2001) 
exopolysaccharides  Murine sarcoma and 
leukemia viruses 
Radonic et al., (2010) 
Talyshinsky et al., 
(2002) 
Bacillariophyta    
Sulfated 
polysaccharide 
Navicula directa HSV-1, HSV-2, 
Influenza-A; HIV-1 
Lee et al., (2006) 
Ahmadi et al., (2015) 
Naviculan    
Dinoflagellates    
Extracellular 
polysaccharide 
Gyrodinium 
impudicum 
EMCV 8 , influenza A 
virus 
Yim et al., (2004) 
Kim et al., (2012) 
p-KG03    
Extracellular 
sulfated 
polysaccharide A1 
and A2 
Cochlodinium 
polykrikoides 
Influenza A and B 
viruses, RSV-A9, RSV-
B, parainfluenza-2 
Hasui et al.,(1995) 
Compounds Microorganisms Viruses References 
Chlorophyta    
Sulfated 
polysaccharide 
Chlorella vulgaris 
Dunaliella salina  
C.autotrophica 
(chlorella), Ellipsoidon 
sp.  
Haematococcus 
pluvialis 
HSV-1  
VHSV10, ASFV11  
HSV-1 
Santoyo et al. (2012) 
Fabregas et al. (1999) 
Santoyo et al. (2012) 
  Sulfated exopolysaccharides from marine microalgae are believed to interact with 
the first phase of the development of some enveloped viruses (Batinic and Robey, 
1992), therefore blocking the virus from entering the host cells and providing 
competitive advantages due to their wide antiviral range, such as against HSV and HIV-
1 (Amaro et al., 2011; Damonte et al., 2004). The sulfated polysaccharide by a cell wall 
of the red microalga Porphyridium sp. demonstrated remarkable antiviral capacity                                                         6 Herpes simplex virus 1 and 2  7 is one of eight herpesviruses 
8 encephalomyocarditis virus 
9 Respiratory Syncytial Virus Subtypes A and B 10 Viral hemorrhagic septicemia  11 African swine fever virus  
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versus HSV type 1 and 2, both in vitro by culturing cells and in vivo by experimenting in 
rats and rabbits (Huleihel et al., 2002). 
  Certain microalgae from different taxonomic categories generate sulfated 
polysaccharides with antiviral activity. For example, the diatom Navicula directa creates 
an extracellular sulfated polysaccharide, naviculan, consisting of galactose, xylose, 
rhamnose, fucose, mannose, and sulfate. Naviculan has a strong antiviral activity 
against HSV-1 and HSV-2 and influenza viruses by impeding the early stages of 
viral proliferation and may block viral incorporation in host cells (Lee et al., 2006). 
  The Cochlodinium polykrikoides dinoflagellate provides extracellular sulfated 
polysaccharides consisting of glucose, galactose, mannose, uronic acid, and sulfate. 
The development of HIV-1, flu A and B viruses, and respiratory syncytial viruses A and 
B have been impaired by these polysaccharides (Hasui et al., 1995). 
 
Proteins, Lipids, Pigments 
  The application of microalgal extracts in antiviral therapy appears to be a 
particularly attractive choice due to the large chemical diversity of their bioactive 
compounds which are less likely to product resistant mutants than other compounds 
during the viral life cycle (Fábregas et al., 1999; Falaise et al., 2016). Firstly, various 
microalgae organisms generate antiviral proteins, such as lectins which are 
carbohydrate-binding proteins or glycoproteins. During the last decade, the 
researchers found that numerous lectins creating anti-HIV activity by attaching directly 
and closely to carbohydrate parts at the glycosylated envelope of HIV. Secondly, many 
algal lipids have the antiviral activity to a smaller extent relative to polysaccharides and 
proteins (Dewi et al., 2018).  
  The most common are sulfolipids and glycolipids, such as 
sulfoquinovosyldiacylglycerides (SQDG), monogalactosyldiacylglycerides (MGDG). 
Finally, microalgae formed specific pigments demonstrating similar biological anti-viral 
activities. Chlorophyll substances from Dunaliella primolecta have shown anti-HSV 
(Herpes Simplex) function (Ohta et al., 1998). Moreover, a water-soluble component 
containing marennine, the blue pigment formed by the Haslea ostrearia marine 
diatom, was able to block the replication of HSV-1 in vitro (Bergé et al., 1999). 
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3.3. Antibacterial activity 
  After Pratt et al. pioneering work in the 1940s, which revealed chlorellin's 
antibacterial activity, the quest for antibacterial components from microalgae (Falaise 
et al., 2016) has created growing interest. This antibiotic, a synthesis of the green fatty 
acids Chlorella sp., was demonstrated to be efficient for various Gram positive (G+) and 
Gram negative (G−) bacteria (Pratt et al., 1944). 
  Fatty acids (Desbois et al., 2009; Khoeyi et al., 2012; Sanabria-Ríos et al., 2014), 
polyphenols (López et al., 2015), biphenyls (Volk and Furkert, 2006), polysaccharides 
(Geresh and Malis, 1991; Raposo et al., 2015), and nanoparticles12 (Garcıa et al., 2014; 
Merin et al., 2010; Patel et al., 2015) consist of various antibacterial components from 
microalgae. Those substances have different mechanisms to prevent the growth of 
bacteria. Fatty acids can affect the permeability of the bacterial cell wall by penetrating 
its long carbon chains (Galbraith and Milter, 1973), they can also impede the 
development of some bacterial enzymes (Kurihara et al., 1999) and restrict nutrient 
uptake from the atmosphere, blocking bacterial growing (Desbois and Smith, 2010). 
  Polyphenol and biphenyl compounds from microalgae induce bacterial cell lysis by 
interfering with membrane permeability and solidity of the phospholipid layer (Daglia, 
2012; Jain et al., 2013). Moreover, multiple antibacterial modes of action remain to be 
examined, such as nanoparticles limiting bacterial growth (Shankar et al., 2016). 
Therefore, screening studies discovered that microalgae are a source of various 
antimicrobial agents, due to their species chemodiversity (e.g., Mudimu et al., 2014). 
Lastly, a compound's antibacterial efficiency can vary depending on the bacteria's Gram 
type. The bacteria (G−) tended to be more tolerant than the bacteria (G+) to several 
antibiotic agents. An exception is the appearance of lipopolysaccharides of microalgae 
in (G−) bacteria which tends to inhibit the penetration of extracellular compounds into 
the bacterial cells (Takeuchi et al., 1999). 
 
Green Microalgae 
  Recently, microalgae antibacterial compounds have been examined, attesting the 
range of compounds being analyzed with biological activities and the abundance of                                                         12 nano-sized materials 
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microalgae organisms (Amaro et al., 2011; Falaise et al., 2016; Pradhan et al., 2014). 
Table 3 presents several known compounds with antibacterial efficacy extracted from 
microalgae. 
Table 3: Antibacterial compound from eukaryotic microalgae: Modified by Dewi et al., 2018 
Microalgae Antibacterial Compound Examples of  
Target Bacteria 
References 
Green Microalgae    
Chlorella sp. Mixture of fatty acids Bacillus subtilis, 
Staphylococcus aureus, 
Streptococcus pyogenes, 
Escherichia coli, 
Pseudomonas aeruginosa 
Pratt et al. (1944) 
C. vulgaris Phenolic compounds E. coli, Klebsiella sp., 
Bacillus sp., 
Pseudomonas sp. 
Syed et al. (2015) 
C. ellipsoidea Saturated and 
unsaturated fatty acids 
Propionibacterium acnes Sibi (2015) 
C. protothecoides    
C. pyrenoidosa    
Chlorococcum 
HS-101 
Alpha-linolenic 
polyunsaturated  
fatty acid 
B. subtilis, B. cereus, 
S. aureus, MRSA13, 
Enterobacter aerogenes 
Ohta et al. (1995) 
C. humicola Pigments (carotenoid, 
chlorophyll) 
B. subtilis, S. aureus, 
E. coli, P. aeruginosa, 
Salmonella typhimurium, 
Klebsiella pneumoniae, 
Vibrio cholerae 
Bhagavathy et al. 
(2011) 
Dunaliella 
primolecta 
Alpha-linolenic 
polyunsaturated fatty 
acid 
B. cereus, B. subtilis, 
S. aureus, MRSA, 
E. aerogenes 
Ohta et al. (1995) 
D. salina Indolic derivative, 
polyunsaturated fatty 
acids, beta-ionone and 
neophytadiene 
S. aureus, E. coli, 
P. aeruginosa 
Herrero et al. (2006) 
   Mendiola et al. (2008) 
   Pane et al. (2015) 
Microalgae Antibacterial Compound Examples of  
Target Bacteria 
References 
Haematococcus 
pluvialis 
Short-chain fatty acid S. aureus, E. coli Santoyo et al. (2009) 
Scenedesmus 
obliquus 
Long-chain fatty acid S. aureus, E. coli, 
P. aeruginosa, 
Salmonella sp. 
Guedes et al. (2011) 
Tetraselmis suecica Fatty acid Proteus sp., S. pyogene Bai and  
Krishnakumar (2013) 
Red microalgae    
Porphyridium 
aerugineum, 
P. cruentum 
Phycobiliprotein S. aureus, S. pyogenes Najdenski et al. (2013) 
  Salmonella typhimurium  
P. cruentum Extracellular sulfated 
polysaccharides 
S. enteritidis Raposo et al. (2014b) 
Rhodella reticulata  S. aureus, S. pyogenes, 
B. cereus, S. typhimurium 
Najdenski et al. (2013) 
Diatoms    
Chaetoceros 
muelleri 
Unsaturated fatty acid B. subtilis, S. aureus,  
E. coli 
Mendiola et al. (2008) 
Phaeodactylum 
tricornutum 
Fatty acid B. cereus, S. aureus,  
S. epidermidis, MRSA 
Desbois et al. (2009) 
Haslea 
karadagensis 
Marennine-like pigment Polaribacter irgensii, 
Pseudoalteromonas 
elyakowii, V. aestuarianus 
Gastineau et al. 
(2012b) 
Haslea ostrearia Marennine P. irgensii, P. elyakowii,  
V. coralliilyticus, V. 
tubiashii, V. aestuarianus 
Gastineau et al. 
(2012a) 
   Gastineau et al. 
(2014) 
   Falaise et al. (2016) 
                                                         
13 Methicillin-resistant Staphylococcus aureus 
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  The green microalgae of the Chlorella group contain many antimicrobial compounds, 
such as fatty acids, pigments, and phenolic compounds (Jorgensen, 1962). Bacteria like 
Escherichia coli, Klebsiella sp., Bacillus sp., and Pseudomonas sp. can be inhibited by 
phenolic ingredients such as flavonoids and tannins from methanolic extracts of 
Chlorella vulgaris (Syed et al., 2015). Lipid derivatives of Chlorella ellipsoidea, Chlorella 
protothecoides, and Chlorella pyrenoidosa show a lipase activity reduction of 
Propionibacterium acnes (Sibi, 2015), a (G+) anaerobic bacteria. Furthermore, Ferreira 
et al. (2016) analyzed a silver nanoparticle, biosynthesized from C. vulgaris, as an 
antibacterial component against Staphylococcus aureus and Klebsiella pneumoniae. 
Results indicate that silver nanoparticles blocked both bacteria's activity by 98 percent, 
at levels as low as 10 μg /mL. Dunaliella primolecta methanolic samples indicated 
significant activity against methicillin-resistant S. aureus (MRSA) (Ohta et al., 1995).  
  Additionally, methanolic compounds from Dunaliella tertiolecta showed in vitro 
antibacterial function towards S. Aureus and P. aeruginosa, bacteria that can create 
external otitis (Pane et al., 2015). D. Salina contains various exopolysaccharides, which 
are recognized as strong antibacterial agents against E. Coli and S. aureus (Mendiola et 
al., 2008). The green microalga Tetraselmis suecica was also confirmed to inhibit the 
growth of bacteria. In one study a combination of chloroform and ethanol compounds 
is powerful versus Proteus sp. and S. pyogenes bacteria. The fatty acids were identified 
as the bioactive compounds in T. suecica (Bai and Krishnakumar, 2013). 
 
Red microalgae 
  Porphyridium aerugineum phycobiliproteins contain phycocyanin that is 
documented to impede the production of the (G+) S. aureus14. In Porphyridium 
cruentum, phycoerythrin was described as an antibacterial ingredient against S. aureus 
(Najdenski et al., 2013), and 1% of extracellular sulfated polysaccharides (EPS) 
demonstrated activity against E. coli and S. aureus (Raposo et al., 2014b). Liberman et 
al. (2016) assessed the antibacterial behavior of the Porphyridium sp. polysaccharide 
combination with ion Zn2+. In addition to the Porphyridium species, in vitro 
experiments with the red microalga Rhodella reticulata using exopolysaccharides                                                         14 Staphylococcus aureus is a Gram-positive, round-shaped bacterium 
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observed antibacterial activity against S. Auroreus, S. Pyogenes, Cereus Bacillus, and 
Typhimurium Salmonella (Najdenski et al., 2013). 
 
Diatoms 
It is also recognized that several diatom microorganisms have an antibacterial 
function. Seraspe et al. (2012) analyzed N-hexane, methanol, dichloromethane, and 
ethyl acetate extracts of Chaetoceros calcitrans and this in vitro assessment proved a 
growth inhibition of S. aureus, B. subtilis and E. coli.  Purified by the diatom 
Phaeodactylum tricornutum, the fatty acid eicosapentaenoic acid (EPA) demonstrated 
important in vitro activity against S. Aureus (Desbois et al.,2009). 
  Methanol extracts of Skeletonema costatum showed within vitro assessment 
effectiveness against the pathogenic bacteria Proteus mirabilis, Proteus vulgaris, 
Proteus aeruginosa, Salmonella paratyphi B, S. aureus, and Vibrio cholerae. (Daniel, 
2016). Unpurified compounds of the diatom S. marinoi, under phosphate culture and 
nitrogen deprivation, impede S. aureus growth (Lauritano et al., 2016). A concentration 
of 100 μg/mL, crude extracts from Amphora cf capitalata, and Nitzschia comunis 
stopped S. aureus production by 83% and 100%, respectively (Montalvão et al., 2016).  
 
3.4. Antifungal activity 
  Many fungal species have reported an invasive infection that can often damage 
serious organs such as the skin and the nails, lungs, brain, and all the parts of the oral 
and genitals (Husain et al., 2001; Tyagi, 2016). The genera Candida, Cryptococcus, 
Aspergillus, and Pneumocystis of fungi are blamed for more than 90 percent of all 
fungal-related deaths in persons with reduced immunity (Brown et al., 2012). For 
example, on the one hand, dermatophytes are responsible for superficial skin and nails 
infections, on the other hand, Candida species causes candidiasis, a very frequent 
fungal infection (Tong and Tang, 2017). Candidiasis generally affects the digestive and 
respiratory system, bloodstream, and vagina. Cryptococcus neoformans, also causes 
another life-threatening infection, cryptococcis. This uncapped yeast can influence the 
central nervous system (CNS) and causes brain and meninges inflammation (Chrétien et 
al., 2002), but also inflammation of lungs (Fang et al. 2015). Aspergillosis is also a very 
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dangerous fungal infection, mainly due to Aspergillus fumigatus and A. Flavus which 
creates pneumonia and weakens the immune system (Latge, 1999). Moreover, these 
aggressive fungi, creates nosocomial infections which lead to an increased death rate in 
intensive care units (Majumdar and Padiglione, 2012). Pneumocystis infections consist 
of another usual respiratory disease, life-threatening when HIV or prolonged 
immunosuppressive therapy damages immunity (Brown et al., 2012). 
  Generally, fungal infection therapy has become increasingly difficult because of 
strain resistance (Ghannoum and Rice, 1999). Currently, a preferred approach to deal 
with invasive fungal infection is a combination of antifungal medications (Carrillo-
Munoz et al., 2014). Nevertheless, due to the fast and significant spread of resistant 
fungi, other therapeutic approaches may need to be developed that require new 
antifungal drugs. Specific research on the availability of new sources of antifungal 
agents has been performed. Microalgae because of their richness in bioactive 
compounds and their versatility, become one of the most valuable candidates of new 
antifungal medicines (Skulberg, 2000). 
 
Green and Red Microalgae 
Many green microalgae contain organically active compounds, for example, the 
Chlorella and Scenedesmus genera, which may be antimicrobial agents. For instance, 
the culture liquids from C. vulgaris and C. ellipsoidea had antifungal activity against 
Candida kefyr, Aspergillus fumigatus, and Aspergillus niger (Ghasemi et al., 2007). 
Often these bioactive substances from microalgae are diffused in organic solvents. 
Thus, extracts with various organic solvents (acetone, benzene, chloroform, 
diethylether, ethylacetate, ethanol, hexane, and methanol) of the freshwater 
Chlorococcum humicola demonstrated antifungal function versus Candida albicans, A. 
niger, and A. flavus, and the most powerful from benzene extracts (Bhagavathy et al., 
2011).  
  Abedin and Taha (2008) also measured the antifungal activity of solvents like 
acetone, ethanol, diethylether, and methanol extracts of Chlorella pyrenoidosa and 
Scenedesmus quadricauda against A. niger, A. flavus, Penicillium herquei, Fusarium 
moniliforme, Alternaria brassicae, Helminthosporium sp., Saccharomyces cerevisiae, C. 
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albicans. Algal extracts showed different inhibitory effects of the fungi tested, with 
ethanol extracts to be the most effective. 
  Because of the low number of available red microalgae, only a few experiments 
have taken place, compared to other classes. This explains why Mudimu et al. (2014) 
noticed an inhibition activity against C. albicans only in 2 out of 88 microalgal strains, 
Heterochlorella luteoviridis and the rhodophyte Porphyridium purpureum. 
For example, phycobiliproteins removed from Porphyridium aerugineum and P. 
cruentum presented antifungal action against C. albicans, as well as the 
exopolysaccharides of Rhodella reticulata (Najdenski et al., 2013). 
 
Diatoms and Dinoflagellates 
  A large number of diatoms antimicrobials are also a powerful antifungal. 
Polysaccharides from Asterionella glaciallis, Chaetoceros lauderi, and Chaetoceros 
diadema have strong antifungal function against Candida pseudotropicalis, 
Trichophyton rubrum, Fusarium fuhum, Fusarium oxysporum, and Colletotrichum 
acutatum (Viso et al., 1987). Besides, since the antimicrobial impact depends on the 
emitter as well as on the target organism, Chaetoceros Lauderi show the highest 
efficiency towards Fusarium oxysporum. 
  The efficacy of the antifungal agent also depends on the extraction solvent. Walter 
and Mahesh (2000) tested 11 marine diatoms for their antimicrobial function towards 8 
pathogenic fungi. Eight of the 11 diatom species examined showed 
important antifungal behavior, which differed in intensity accordingly to the solvent 
and the target species. The strongest antifungal activity was of Thalassiothrix 
frauenfeldii and Navicula sigma, and Aspergillus niger and Cryptococcus neoformans 
were the most vulnerable fungi. Acetone extracts seemed to have the lowest antifungal 
efficacy, the lowest chloroform-methanol, and methanol-water proportions. 
  Finally, several dinoflagellates can produce toxins, but some of these toxins are 
considered antimicrobial (Camacho et al., 2007; Gallardo-Rodríguez et al., 2012). 
Consequently, the dinoflagellate Gambierdiscus toxicus produces polyethers, 
gambierdic acids with antifungal effectiveness (Nagai et al., 1993). Gambierdic acid A 
and B impeded fungal growth of A. niger and A. fumigatus, as the most sensitive 
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species. Antifungal agents are extracted from Amphidinium sp. dinoflagellates such as 
polyol compounds (karatungiols A and B) which block A. niger (Washida et al., 2006). 
 
3.5. Potential of Microalgae in Cardiovascular Disease Prevention 
The primary cause of mortality and premature death is cardiovascular disease (CVD). 
It covers coronary heart problems, stroke, peripheral artery disease, and heart failure. 
Hypertension, hyperlipidemia, and diabetes are the major risk conditions of 
atherosclerosis. Different results show that in addition to their specific fatty acid 
composition, microalgae may also minimize some of these risk factors and provide a 
dietary preventive strategy intrinsically (He et al., 2004). The plasma cholesterol level in 
rats has been decreased with the use of red microalga Porphyridium sp. (Dvir et al., 
2000). This effect is mainly due to the microalgae's polysaccharide component, but 
other components such as phycocyanin can influence lipid metabolism (Nagaoka et al., 
2005). In addition to these animal studies, microalgae's hypolipidemic activity was used 
in human clinical studies (Nazih and Bard, 2018). 
  The Omega-3 Index was introduced in 2004 as a modern measure of risk concerning 
cardiovascular mortality. Though initially synthesized by microorganisms in the seas, 
the long-chain n–3 (omega-3) fatty acids eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) are mainly produced from fish consumption (Harris, 2014). 
Fish and fish oil are indeed the main sources of polyunsaturated fatty acids (LC-PUFA) 
in the omega-3 long-chain, however, contaminants or toxins have been increased in 
fish. Also, using fish oil is relatively poor in part owing to odor, taste, and oxidation 
issues (Mimouni et al, 2015). Because of these drawbacks, studies have been published 
for an application of microalgae (marine or freshwater) in human aliment, as a new 
source of fatty acids, according to their versatility of lipids and fatty acids. Even if still in 
its development, a near-infinite supply of these essential nutrients will be generated by 
commercial production of EPA and DHA from nonfish origins (Adarm-Vega et al, 2012).  
  Freshwater microalga Chlorella vulgaris produces oleic, palmitic, and linolenic acids 
(Mendes et al., 1995). Dunaliella salina generates fatty acids in a percentage of about 
80% of the overall fatty acids (Herrero et al., 2006). Porphyridium species can also 
extract gamma-linolenic and arachidonic acids. Other species of microalgae synthesized 
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omega-3 fatty acids, such as EPA in genus Nannochloropsis, Phaeodactylum, Nitzschia, 
Odontella, Isochrysis, and Pavlova species, although DHA can be found in the 
Crypthecodinium, Pavlova and Schizochytrium ones. Additionally, few species of these 
microalgae are approved for commercial use as nutritional supplements, Chlorella, 
Crypthecodinium, Dunaliella, and Odontella (Rodriguez-Meizoso et al., 2010).  
  In the latest decades from the advent of healthy supplements with probiotics, the 
health benefits of microalgae have been gradually recognized and accepted, especially 
in cardiovascular diseases. Another freshwater microalga, Chlorella sp., has had many 
health benefits, such as a reduction of glycemia and cholesterolemia. Such organisms 
could also be used to improve the development of cytokines to enhance the response 
of the immune system (Barrow and Shahidi, 2008).  
  Although few strains of microalgae have been approved for human consumption, 
animal models have performed several trials with several microalgae. Also, 
Porphyridium cruentum lyophylisate was utilized for the Syrian golden hamster as a 
food additive. This test showed the reduction in cholestine distribution (dose-
dependent) and body fat (percentage-expressed) in hypercholesterolaemic animals 
with the use of this microalgae biomass (Harding et al., 2009).  
  Retinoids, the metabolic components of carotenoids, are significant in the growth of 
the cardiovascular system during embryogenesis. This function is regulated by 
triggering the RAR (retinoic acid receptor) in the signal transduction pathways 
controlling the growth of embryos, tissue homeostasis, and cell division and 
multiplication. Nonetheless, earlier studies have shown that retinoids play a significant 
role in cardiac repair after myocardial infarction in hypertensive rats (Paiva et al, 2005). 
Carotenoids, these plant pigments synthesized first retinol then retinoic acid (RA) in the 
intestine, the liver, and eventually in target cells. RA is important to modify several 
biological processes such as cell replication and growth, vision, bone formation, 
metabolism, and immunology. The medical research of retinoid derivatives as 
medicines for the treatment of many diseases is, therefore, very promising (Das et al, 
2014). 
Dunaliella Salina which is unicellular and part of the phylum chlorophylta, is known to 
be the largest natural source of large carotenoids (Phadwal et al, 2003). Zeaxanthin, 
one of nature's most abundant carotenoids, is an antioxidant. Consequently, 
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Zeaxanthin isolated from D.salina can be used as a natural medicinal agent by 
activating retinoid receptors in cardiac tissue to improve heart damage (El-Baz et 
al,2019), while it is proven a promising curative and prophylactic activity of D. salina 
against cardiac dysfunction in aging rats (El-Baz et al, 2018).  
  Astaxanthin is a carotenoid of xanthophyll contained in microalgae. It is an 
antioxidant with anti-inflammatory effects and therefore has potential as a therapeutic 
drug in coronary atherosclerotic diseases. A small number of clinical trials have 
examined the efficacy of astaxanthin on oxidative stress and inflammation that are 
important to the pathophysiology of cardiovascular diseases. Laboratory research of 
multiple species using a myocardial ischaemia-reperfusion model has shown that 
astaxanthin supports myocardium both orally and intravenously before the ischaemic 
event is inducted (Fassett and Coombes, 2011). 
  Astaxanthin has a special molecular structure, which controls its intense antioxidant 
activities by purifying singlet oxygen15 and free radicals. Astaxanthin was indicated to 
reduce oxidation of low-density lipoprotein (LDL) (bad cholesterol) and to improve 
clinical trial levels of high-density lipoprotein (HDL)-cholesterol and 
adiponectin (peptide) (good cholesterol particle). Current evidence indicates that the 
potential of astaxanthin for improving oxidative stress, inflammation, lipid metabolism, 
and glycosemia may contribute to preventative measures against atherosclerotic 
cardiovascular disease (Kishimoto et al, 2016). 
  The largest amount identified of astaxanthin in nature is Haematocaccus pluvialis, a 
chlorophyte alga that has to turn into a major source of astaxanthin in the food field 
(Lorenz and Cysewski, 2000; Yuan et al, 2011). In 1987, the United States FDA 
permitted astaxanthin as a food supplement for the aquaculture sector and in 1999 
authorized astaxanthin as a nutritional supplement (Guerin et al, 2003).  
 
 
 
 
                                                          15 gaseous inorganic chemical  
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Table 4. Summary of the anti-atherosclerotic activity of astaxanthin:  
Modified by Kishimoto et al, 2016. 
  Anti-Oxidation  
 
 
Iwamoto et al. (2000)  
 
Healthy volunteers (n 
= 24)  
 
Open labeled; 2 weeks; 
1.8, 3.6, 14.4 or 21.6 
mg/day  
 
 (decrease)LDL oxidation  
 
Nakagawa et al. 
(2011)  
 
Middle-aged subjects 
(n = 30)  
 
Randomized, double-
blind, placebo 
controlled; 12 weeks; 6 
or 12 mg/day  
 
 (decrease) phospholipid 
peroxidation 16  in 
erythrocytes  
 
Karppi et al. (2007)  
 
Healthy non-smoking 
males (n = 40)  
 
Randomized, double-
blind, placebo 
controlled; 12 weeks; 8 
mg/day  
 
 (decrease) plasma 12- 
and 15-hydroxy fatty acids  
 
Choi et al. (2011)   
 
Overweight adults (n 
= 23)  
 
Randomized, double-
blind; 3 weeks; 5 or 20 
mg/day  
 
  (decrease) plasma 
MDA17(marker of oxidative 
stress), isoprastane 18 
(increase) SOD19, TAC 20 
 
 
  Anti-Inflammation  
 
 
Park et al. (2010)  
 
Healthy female 
students (n = 42)  
 
Randomized, double-
blind, placebo 
controlled; 8 weeks; 0, 
2 or 8 mg/day  
 
 
 (decrease)plasma 8-
hydroxy-2- 
deoxyguanosine21 , CRP22 
 
   
Lipid Metabolism-
Modulating  
 
 
Yoshida et al. (2010)  
 
Non-obese subjects 
with mild 
hypertriglycemia (n = 
61)  
 
Randomized, placebo-
controlled study; 12 
weeks; 0, 6, 12 or 18 
mg/day  
 
 (decrease) serum TG, 
(increase) HDL-C, 
adiponectin23 
 
Ursoniu et al. (2015)  
 
 Meta-analysis of seven 
randomized controlled 
studies  
 
No important effect on 
plasma lipid profile (LDL-C, 
HDL-C, TG24)  
 
  Glucose Lowering  
 
 
Ursoniu et al. (2015) 
 
 Meta-analysis of seven 
randomized controlled 
studies  
 
Slight reducing reaction to 
plasma glucose  
 
 
 
For clinical settings, the current data may be positive, but the medicinal efficacy of 
this natural compound needs to be identified for human beings.                                                         16 Oxidative degradation of lipids 17 Malondialdehyde (MDA) is one of the final products of polyunsaturated fatty acids peroxidation in the cells. 18 Biomarkers serve as indicators of oxidative stress in cardiovascular diseases. 19 Antioxidant enzyme that reduces harmful free radicals  20 total antioxidant capacity 21 products of DNA oxidation 22 protein, marker of inflammation 23 a protein hormone that is produced by fat cells. 24 Thyroglobulin, glycoprotein produced by the follicular cells of the thyroid  
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3.6. Metabolism 
  Metabolism defines all chemical reactions involved in the preservation of the cell 
and the organism's living state. The major public health concern is metabolic syndrome 
causing dyslipidemia, obesity, and insulin resistance which leads to cardiovascular 
disease and death. Omega-3 PUFA in fish oil is well proven to lower the frequency of 
metabolic syndrome risk elements (Poudyal et al., 2011). An additional source of 
Omega-3 is from Odontellla aurita marine diatom which synthesizes high levels of 
eicosapentaenoic acid (EPA, 25 to 26% of total fatty acids) which is known to obstruct 
cardiovascular risks. O. aurita's efficiency as a food supplement is proved by Mimouni 
et al (2015), in controlling physiological and biochemical parameters involved in 
metabolic syndrome deployment, platelet aggregation,25 oxidative stress which leads 
to cardiovascular health problems.  
  Another serious health problem due to the modern lifestyle is obesity. The anti-
obesity activity of refined FX powder (Phaeodactylum extract (PE)) from microalgae 
Phaeodactylum tricornutum as a functional food has been explored in the other 
research (Koo et al, 2019). PE containing FX exercises anti-obesity functions and 
facilitates lipolysis via lipogenesis inhibition. It is, therefore, a good candidate in the 
production of antiobesity foods and integrated health foods produced by modern 
marine microalgae. 
Diabetes mellitus (DM) is a category of metabolic disorders with a high level of blood 
sugar for a long time. Serious long-term problems from diabetes include heart attack, 
stroke, chronic kidney disease, foot ulcer, and eye injury (www.wikipedia).  
  An assessment of antihyperglycemic and antihyperlipidemic behaviors and weight 
monitoring of Nannochloropsis oculata microalgae (NOM) in Streptozotocin26-induced 
diabetic male rats were performed by Nasirian et al., in 2019. Other studies have 
shown that the treatment of chlorella microalgae in diabetic rats has lowered glucose 
levels and increased insulin levels (Mokady and Sukenik, 1995). In this test, NOM 
therapy significantly decreased plasma TG27, total cholesterol and LDL-C associated                                                         
25 Aggregation of platelets is part of the sequence of events that contribute to thrombal formation (clot). 
26 is consisting an alkylating antineoplastic agent founded in the nature which is very toxic to the insulin-
producing beta cells of the pancreas in mammals.  
27 triglyceride levels  
 31 
with a significant increase in HDL-C rates in diabetic rats in three weeks, showing its 
strong antihyperlipidemic and anti-atherogenic action.  
  Markovits et al. (1992) also stated that dietary fibers existing in Nannochloropsis, in 
particular, insoluble fibers, inhibit intestinal absorption of cholesterol (Kagan et al, 
2014) and have an anti-hypercholestromic effect. Diabetic rats (control group) display 
less body weight than healthy rats. NOM can retain weight in diabetic rats and improve 
metabolic disorders by increasing insulin and reducing the level of glucose. However, 
the antioxidant pigments and EPA28 present in the NOM will retain glucose, insulin, and 
lipid profile values, and can boost body metabolism and therefore maintain weight. 
These findings suggest that NOM can be beneficial for diabetes mellitus care. Further 
research will be needed in the relationship between NOM and diabetes. 
  Moreover, diabetic rats have seen decreased values of glucose and lipid 
(triacylglycerol and cholesterol) and it is a proven loss of weight in groups fed with 
microalgae Isochrisis Galbana. About the synthesis of lipoproteins, this microalga raises 
law lipoprotein content and reduces the concentrations of large lipoproteins (Nuno et 
al. 2013).  
3.7. Respiratory 
  Acute respiratory distress syndrome (ARCS) is considered an immediate start of 
noncardiogenic edema and as a result of severe inflammatory processes, an obstacle of 
gaz-exchange. Ω-3 fatty acids have been suggested to modulate the inflammatory 
response in ARDS, even though the data so far collected is limited (García de Acilu et al, 
2015). 
3.8. Inflammation-Oxidative Stress-Allergies 
  The incidence of oxidative stress and inflammatory disorders in developed countries 
is steadily growing (Bonomini et al, 2008; Molodecky et al, 2012). The development of 
these conditions may also be correlated with cancer (Reuter et al, 2010; Siegel et al, 
2016). Studies are, therefore, trying to trace new compounds that can be applied to 
decrease inflammation, oxidative stress and cancer cell activity. A lot of proves are 
 32 
available in the literature, indicating that certain microalgae extracts have an anti-
inflammatory effect. Nevertheless, aqueous extracts of both microalgae decreased paw 
edema in rats caused by carrageenan (Guzman et al., 2001).29 The inflammation was 
decreased by 90 percent with Chlorella stigmatophora at a dosage of 250 mg/kg and 
with Phaeodactylum tricornutum by 87%. The anti-inflammatory activity of coarse 
extracts was 25%-30% higher than indomethacin30, the pharmacological equivalent 
(Nazih and Bard, 2018). 
  The researchers proposed that these results could be due to phycocyanin because 
both oxidative stress and edema were prevented by this molecule; this anti-
inflammatory activity may also be due to the presence in microalgae of sulfated 
polysaccharides.  
  In a test utilizing polysaccharides obtained from Porphyridium microalgae, it was 
shown in vitro that these polysaccharides prevented leucocyte chemotaxis and 
endothelial cell adherence. Such compounds have also been evaluated in human 
volunteers with a background of skin allergy to balsam of Peru (Matsui et al., 2003). 
Microalgae-based polysaccharide fractions reduced skin redness even more than an 
active anti-inflammatory compound derived from a cola extract. Such results indicate 
that these extracts might be utilized for external use as effective anti-inflammatory 
drugs. 
  Moreover, Fucoxanthin, this oxygenated carotenoid from diatom Phaeodactylum 
tricornutum, may be used as a new nutraceutical if it also has the positive health 
effects that have already been shown for microalgae carotenoids. In cell-free and cell-
based assays, Fucoxanthin had powerful antioxidant effects. Fucoxanthin's antioxidants 
extracts from P. tricornutum do not vary greatly from astaxanthin, a carotenoid that 
has powerful antioxidant effects produced from the already commercially marketed 
red algae Haematococcus pluvialis. High amounts of fucoxanthin could be found in the 
diet to mitigate the effects of oxidative stress-related diseases. However, because of its 
protective health effect, fucoxanthin may assist in conventional cancer treatment. To                                                                                                                                                                    28 eicosapentaenoic acid, fatty acid 
29 Carrageenans or carrageenins are sulfated polysaccharides derived from red edible seaweeds. 30 An anti-inflammatory medicine 
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further endorse these observations, human trials are needed in the future (Newman et 
al, 2019). 
  Finally, several microalgae species have been identified as anti-allergic. The 
existence of an antiallergic substance in the ethanol-insoluble fraction of Dunaliella 
salina is strongly suggested (Fujitani et al., 2001). For their anti-allergy characteristics, 
other species such as Chlorella vulgaris or Chlorella pyrenoidosa (Chlorophyta) have 
also been presented (Vo et al., 2012). 
3.9. Immunology (various & infectious diseases) 
  It is difficult to differentiate the immunomodulative effect of microalgae from the 
anti-inflammatory effect. The reported capacity of microalgae polysaccharides to 
suppress leucocyte migration may be correlated with their anti-inflammatory function 
(Matsui et al., 2003). Nevertheless, certain microalgae have been shown to have a 
strong stimulating influence on immune cells.  
  This was the example of Phaeodactylum tricornutum, which was demonstrated to 
trigger phagocytosis and the sulfated polysaccharide from Chlorella stigmatophora, 
which indicated immunosuppressant functions (Guzman et al., 2003). Gymnodinium 
impudicum sulfated polysaccharides also enable nitric oxide synthesis and induce 
cytokine development in macrophages (Bae et al., 2006). However, in contrast to these 
promising in vitro and animal findings, there is a distinct deficiency of clinical studies to 
suggest that microalgae are of significant interest as a source of compounds for the 
treatment of human inflammation or immunomodulation (Nazih and Bard, 2018).  
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Table 5.  Marine microalgae producing immunomodulatory compounds or displaying 
immunomodulatory properties. IL is for interleukin, PBMC is for human peripheral 
blood mononuclear cells. Modified by Riccio and Lauritano, 2019. 
Microalgae Extract/Fraction/ Compound  
 
Mechanism/ Organism and 
Target Cells (or Model)  
 
Reference  
 
Alexandrium 
tamarense  
 
Total Extract/Fractions  
 
Activation of IL-6/Human 
PBMC  
 
Cutignano et al, 2015 
 
Chaetoceros 
calcitrans  
 
Fractions  
 
Activation of IL-6/Human 
PBMC  
 
Cutignano et al, 2015 
 
Chaetoceros 
socialis  
 
Total extract  
 
Activation of IL-6/Human 
PBMC  
 
Cutignano et al, 2015 
 
 
Chlorella 
stigmatopho
ra  
 
Crude polysaccharide extracts  
 
Activation of phagocytic 
activity - SRBC/Mouse  
 
Guzmán et al, 2003 
 
Chlorella 
vulgaris  
 
Diet supplementation/ 
commercially available pills  
 
 
 
Improve of NK activity and 
serum level of INF- , IL-1 and 
IL-12/Human trials  
 
Kwak et al, 2012 
 
Dunaliella 
salina  
 
Diet supplementation of 
commercially available spray-
dried preparations  
 
MiceNK and Macrophage 
activation/In vivo mice model  
 
Chuang et al, 2014 
Cutignano et al, 2015 
 
Dunaliella 
salina  
 
Fractions  
 
Activation of IL-6/Human 
PBMC  
 
Cutignano et al, 2015 
 
 
Euglena 
gracilis  
 
β-Glucans  
 
Activation of NK cells and 
improve in inflammatory 
mediator/Human PBMC  
 
Barsanti and 
Gualtieri, 2019 
Russo et al., 2017 
 
Gyrodinium 
impudicum  
 
Sulfated exopolysaccharides  
 
Macrophage 
activation/Murine  
 
Bae et al, 2006 
Yim et al, 2004 
 
 
Skeletonema 
costatum  
 
Total Extract/Fractions  
 
 
Activation of IL-6/Human 
PBMC 
Cutignano et al, 2015 
 
Skeletonema 
dohrnii  
 
Total Extract/Fractions  
 
Activation of IL-6/Human 
PBMC  
 
Cutignano et al, 2015 
 
Skeletonema 
marinoi  
 
Total Extract  
 
Activation of IL-6/Human 
PBMC  
 
 
Cutignano et al, 2015 
 
Tetraselmis 
chuii  
 
Orally administration of 
lyophilized microalgae  
 
Increase in hemolytic 
complement activity, 
phagocytic capacity and 
expression levels of β-
defensin, major 
histocompatibility complex  II 
a and colony-stimulating 
factor receptor-1/ Gilthead 
sea bream  
Cerezuela et al, 2012 
Thalassiosira 
weissflogii  
 
Fractions  
 
Activation of IL-6/Human 
PBMC  
 
Cutignano et al, 2015 
 
Tribonema 
sp.  
 
Sulfated polysaccharides  
 
Macrophage proliferation and 
improved expression of 
cytokines/Mouse 
Chen et al, 2019 
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  As stated in Table 5, dried algae and crude extracts have been effective versus many 
cells of the immune system. Cutignano et al., (2015) examined unrefined methanol 
fragments and amounts of different species of microalgae. Fractionation also managed 
to distinguish active fractions for other organisms whose raw methanol extracts were 
not effective (Riccio and Lauritano, 2019). To determine their immunostimulatory 
function, other compounds extracted from microalgae have been studied. Chlorella 
stigmatophora polysaccharide aqueous compounds have been analyzed in vitro and in 
vivo mouse models (Guzmán et al, 2003). Supplementation of microalgae food was also 
correlated with immunostimulatory function. In fact, diet supplements of commercially 
accessible spray-dried products of Dunaliela salina in mice boosted NK (natural killers) 
and macrophage activation, leading to the survival of leukemic mice (Chuang et al, 
2014). 
Table 5 lists the algae with immunostimulatory function. 
 
3.10 Hepatology 
  Chlorella vulgaris has been recorded for reducing dyslipidemia and high blood 
pressure; Its impact on inflammatory and insulin-resistant biomarkers, however, has so 
far not been discovered. Non-alcoholic fatty liver disease (NAFLD) is strongly associated 
with insulin-resistance and inflammation as a hepatic complication of metabolic 
syndrome. C. vulgaris supplementation may have beneficial effects as far as glucose 
homeostasis, insulin condition, and biomarkers related to inflammation in patients with 
NAFLD. C. vulgaris supplementation could be considered as a part of treatment for 
weight loss and improvement of glycemic situation and reduction of hs-CRP31 together 
with the improvement of the liver condition in NAFLD as stated Ebrahimi- Memeghani 
et al. (2017). 
 
 
 
                                                         31 The increased risk of heart attack is associated with high levels of hs-CRP (high sensitivity C-reactive protein in our 
blood) 
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3.11 Dermatology 
 
  Astaxanthin, a secondary metabolite produced in nature by a series of bacteria, 
microalgae, and yeasts, is xanthophyll carotenoid. Traditionally, chemical synthesis has 
been used for commercial production, but the Haematococcus pluvialis microalgae 
seem to be the most important path for its commercial biological supply. Because of its 
common and complex function in skin biology, astaxanthin has various health benefits 
and significant nutraceutical uses in dermatology (Davinelli et al, 2018). The 
Haematococcus pluvialis chlorophyte algae have the largest potential for the 
concentration of ASX (Boussiba, 2000). The strong antioxidant function and special 
molecular and biochemical properties of ASX have recently drawn researchers' interest, 
for the treatment and prevention of skin disease. Comparative studies studying 
carotenoid photoprotective activity have found ASX to be a supreme antioxidant and 
more antioxidant compared to canthaxanthin and carotene in human epidermic 
fibroblasting (Camera et al, 2009).  
  Therapy also, with ASX prevents deleterious effects of UV by reducing the 
production of UV-induced reactive nitrogen, inflammatory cytokine, and keratinocyte 
apoptosis. Inhibitory properties of ASX on iNOS32 are important in developing anti-
inflammatory medicines for skin inflammatory conditions like psoriasis and atopic 
dermatitis (AD) (Park et al, 2017). As far as immune effects are concerned, ASX greatly 
affects immune function across in vitro and in vivo assays (Lin et al, 2015). In several 
studies, ASX increased its natural killer activity (NK) and indicated that ASX may control 
NK cells, which serve as a tumor and virus-cell immunosurveillance system (Chew et al, 
2011). Moreover, ASX effectively eliminates in vitro cell damage from free radicals and 
MMP-133 entry into the skin after UV radiation (Suganuma et al, 2010). In specific, ASX 
was able to minimize the damage of DNA and influence DNA repair kinetics (Santocono 
et al, 2006). To fully understand ASX skin activities, further, systematic research will be 
required. 
                                                         32 Nitric oxide synthases (NOSs) are a family of enzymes catalyzing the production of nitric oxide (NO) from L-
arginine.  
33 Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation,  
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Table 6: Studies on skin and astaxanthin. Modified by: Davinelli et al, 2018. 
Intervention 
 
Study Design 
 
Outcomes 
 
Author, Year 
 
Administration of ASX 
capsules 
Randomized  
double-blind, controlled 
study  
 
p DNA damage 
biomarkers;  
n of NK cells, T 
cells, B cells, and 
IL-6  
Park, 2010  
 
Administration of ASX 
capsules  
Monitoring of oxidative 
stress  
and skin aging  
p MDA;  
pRSSC  
Chalyk, 2017  
 
Administration of ASX 
capsules  
Randomized,  
double-blind, parallel-group,  
placebo-controlled  
pWrinkle 
parameters;  
p IL-↵  
Tominaga, 2017  
 
Administration of ASX 
cream  
Pilot study 34 
 
pWrinkle 
parameters  
Seki, 2001  
Topical application of 
ASX  
Pilot study  perythema  Yamashita, 
1995  
Administration of ASX 
capsules  
Randomized, single-blind,  
placebo-controlled  
pWrinkle 
parameters  
Yamashita, 
2006  
 
Oral and topical 
treatment with ASX  
N/S  
 
pWrinkle 
parameters  
Tominaga, 2009  
 
Two oral forms (ASX 
capsules; tablets 
collagen)  
 
Randomized,  
double-blind placebo-
controlled  
 
nviscoelastic 
parameters;  
pTEWL; " 
procollagen type 
I;  
nMMP-1 and  
pMMP-12  
Yoon, 2014  
 
Capsules of ASX 
combined with topical 
application of ASX  
 
Open-label noncontrolled  
 
pwrinkles;  
page spot size;  
n"elasticity;  
n"skin texture  
 
Tominaga, 2012  
 
Administration of ASX 
capsules  
 
Randomized double-blind 
controlled  
 
pwrinkles;  
n"elasticity;   
pTEWL;  
n"moisture 
content;  
psebum oil  
Tominaga, 2012  
 
Abbreviations: "nincrease;pdecrease; ASX, astaxanthin; NK, natural killer; IL-6, interleukin-6; MDA, malondialdehyde; 
RSSC, residual skin surface components; N/S, not specified; TEWL, transepidermal water loss; MMP, matrix 
metalloproteinase. 
 
 
                                                         34 A pilot study is a small scale preliminary study  
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3.12 Neuroscience 
  The disorder of Parkinson is mainly characterized by dopaminergic 35  neuron 
degradation. Neuroinflammation is an important element that damages cells during 
disease progression, and experimental settings have been effective in reducing the 
inflammatory process. Fractalkine36  signals have proved to be a crucial path in 
inflammatory cell death in animal PD models. Astaxanthin has several biological 
functions, many of which seem to be specifically contrasting with the pathological 
mechanisms involved in SN37 neurodegeneration. The two promising new therapeutic 
agents for PD diagnosis and management include both fractalkine and astaxanthin 
(Grimming et al., 2016). 
  Alzheimer’s Disease (AD) is a neurological dysfunction occurring through complex 
mechanisms of pathology and physiology. AD leads to dementia, cognitive decline, loss 
of synapses and cholinergic neurons, and death. Increasing numbers of AD patients 
have centered research into new drugs with minimal or no side effects relative to 
conventional pharmaceutical goods (Rajakumar, 2018). With the expectation that 
experts will soon be able to reverse AD, prevention measures such as lifestyle changes, 
exercise and the use of antioxidants can be taken to delay the progression of AD or to 
mitigate it.  
  So how can microalgae lead to AD treatment? Microalgae are important sources of 
many bioactive materials such as carotenoids, polysaccharides, PUFA's, amino acids 
and proteins, sterols and polyphenols (Olasehinde et al., 2017). A major cause of a 
cognitive decline in patients with AD is accelerated deterioration of the function of 
acetylcholinestrase (AChE).38 ACh, which eventually causes cholineergic damage and 
memory loss, is impaired due to high cholinesterase concentrations (ChE). The AChE 
inhibitory behaviors were contained in extracts from Nannochloropsis oculata, 
Chlorella minutissima, Tetraselmis chuii and Rhodomonas salina (Custódio et al., 2012).                                                         35 Dopamine is one of the chemicals that is responsible for signal processing between the neurons of the brain and 
between nerve cells. 
36 anti-inflammatory cytokine (protein) 
37 The substantia nigra (SN) is a midbrain-located basal ganglia system that plays a significant role in reward and 
mobility. 
38 The major enzyme of neurotransmitter acetylcholine (ACh) is responsible for its hydrolytic synthesis. 
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Extracts from Nannochloropsis sp., Picochlorum sp., and Desmochloris sp. have been 
reported to exhibit BChE39 inhibitory activities (Pereira et al., 2015). 
3.13 Ophthalmology 
  Zeaxanthin, one of nature's most abundant carotenoids, is an antioxidant that 
accumulates in the human eye's retina and protects the retinal system against light-
induced harm. Eating diets containing higher levels of zeaxanthin were found to be 
followed by a low incidence of eye disorders such as age-related macular diseases, and 
cataracts (Madhavan et al, 2018). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                         
39 is a nonspecific cholinesterase enzyme  
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4. European Regulations concerning Microalgae  
  First and foremost, the EU legal framework for microalgae-based medicinal products 
provides certain requirements to secure a high level of public health safety and the 
quality, consistency, and effectiveness of licensed medicinal products. Also, not only 
can it promote the pure functioning of the internal market but also encourage 
innovation progress (Europa, 2019). In Europe, the EFSA (European Food Safety 
Authority) is the competent authority ordered to evaluate the safety of any new 
functional food and supplement ingredient before they are licensed for production and 
market introduction (EFSA, 2019).  
  Three-pillar European legislation applies to the regulation of microalgae or its 
components. The first pillar focuses on general supplement safety, the second one on 
novel ingredients, and the last one on functional nutrition and health claims 
(Novoveská et al, 2019).  
  The safety pillar for microalgae nutraceutical products is mainly combined by the 
European Commission (EC) No 178/200240  and 852/200441 regulations. The EC No 
178/2002 regulation provides a general framework in the development of any 
supplement legislation and determines the general definitions, regulations, and 
responsibilities during the process of production, distribution, and safety at the 
Community level. It also establishes the European Food Safety Authority (EFSA) and 
refers to the commercialization of supplement products using either whole microalgae 
organisms or cells, such as Spirulina and Chlorella, or products that incorporate the 
micro-algae such as the green algae color pasta. Both EC No 178/2002 and 852/2004 
state that all these products based on microalgae are subject to regulations on food 
safety which apply to all supplementary products. Experts issue that safety is an 
important factor in algae-technology especially when algae are generated in open-air 
systems because they have proved to be easily contaminated by other microorganisms 
(Enzing et al, 2014). The safety of the supplement must be checked in extended use                                                         
40 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32002R0178&from=EL 
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because products containing microalgae can not be approved in the European market 
without health evaluation being carried out first (Serafini et al, 2010). 
  
  As far as pharmaceuticals are concerned the European Medicines Agency (EMEA) is 
responsible for securing a commercial authorization application for the EU under the 
“centralized” process. Authorization for use is generally required for 1) all prescription 
biotech products, 2) pharmaceuticals with a newly formed active ingredient used for 
the treatment of HIV, cancer, neurodegenerative disorders, and diabetes, and 3) 
medicinal drugs known as "orphans42". In the sense of "decentralized practice," the 
“mutual recognition” concept extends to the Member States at a national level. 
According to Article 8 of Directive 2001/83/EC43, an authorization may only extend to 
organizations set up in an EU country. Whether the trials are carried out or not within 
the EU, the clinical studies have been morally implemented and protected the privacy 
of individuals. In the appendix of directive 2003/63/EC44, the specific guidelines for 
clinical studies are imposed. The Commission regulations set strict deadlines to 
approve or deny a request for marketing authorization. The EMEA or the Member State 
authorities shall decide in 210 days, in compliance with both decentralized and 
centralized policies. 
  The present European policy on data protection offers a period of “8+2+1” years: 
Generic manufacturers may apply for a marketing license of the provided medicine 
eight years after a marketing authorization of the original product, but only two years 
later could the genetic product in question become available on the market. In case of 
the discovery of new therapeutic benefits in the first 8 years data security can be 
extended by one year. Data and ads on prescription drugs are severely restricted (EU, 
Pharma, legislation, 2019). 
 
 
 
                                                                                                                                                                    41 https://eur-lex.europa.eu/legal-content/EL/TXT/?uri=CELEX%3A02004R0852-20090420 42 The aim of ' orphan drugs ' is to treat diseases that are so rare. 43 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02001L0083-
20121116&qid=1472567249742&from=EN 44 https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A32003L0063 
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5. Swot analysis – A case study of a fictional microalgae-based carotenoid 
production company 
 
  In this section, the strengths, weaknesses, opportunities, and threats (SWOT 
analysis) of a fictional microalgae-based carotenoid production company are 
presented.  
Strengths 
x One of the major strengths of the industry is that there is a rich diversity in terms of 
microalgae and carotenoids. As such, carotenoids based on their antioxidant 
properties continue to increase interest in multiple markets, including food and feed 
products, nutritional products, and cosmetics. 
x Furthermore, the fact that carotenoid’s source is natural, adds an advantage for use 
of the specific products. 
x The further benefits ensuing from other compounds existent in microalgae are 
adding forces to the industry. 
x The ongoing increasing awareness and enthusiasm of consumers for green chemistry 
is another advantage towards future expansion of the specific markets. 
 
Weaknesses 
x One of the major weaknesses of microalgal carotenoids is undoubtedly their 
currently increased costs of production as it can be exhaustive labor and costly 
operation. It is imperative that new methods need to be developed in order to drive 
costs further down. Microalgae are cultivated in open ponds or closed systems 
requiring procedures of mixture and concentration (Chew et al., 2017). These 
procedures are energy consuming and the major concern is minimum energy in 
combination with maximum exploitation of microalgae biomass (Vanthoor-Koopmans 
et al., 2013). Although open structures for cultivation, like open ponds or raceway 
ponds, are more commercially viable for large-scale production, they may not be 
appropriate for cultivating microalgae which would be employed on medicinal or 
pharmaceutical purposes (Chisti, 2007; Milano et al., 2016). On the contrary, closed 
culture systems (e.g. photobioreactors) (Costa and De Morais, 2011; Khoo et al., 
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2011) are more practicable by monitoring the cultivation conditions (e.g., 
temperature, pH and CO2 concentration, and so on), even if capital and operating 
costs rise. 
x The biological systems entail some inherent challenges that constitute another 
weakness of the industry. The microorganisms that manufacture carotenoids typically 
have a low rate and target productivity of carotenoids in accordance with 
recalcitration, resulting in inefficiencies in the extraction of the carotenoid. The 
biomass must be collected after harvesting in a system separating the solid material 
(biomass) from the liquid (cultural medium). The biorefinery process uses microalgae 
biomass to create renewable carotenoid products with many advantages like quick 
maturation, increased demand on the food industry, and selective composition 
(González-Delgado and Kafarov, 2011). 
x Downstream processing and the associated weaknesses of the specific methods 
constitute further disadvantages.  
x Climate limitations for open systems pose further barriers to the industry. 
 
Opportunities 
x There is an increase in end-user applications for carotenoid products formulating 
niche markets. Consequently, the advance of the aquaculture industry, the medicinal 
applications spread, and the increasing preference of consumers for natural 
products, support carotenoids from microalgae potential for future revenue growth 
(Ambati et al, 2019) 
x Improvements in cultivation and downstream processing. The microalgal cultivation 
systems (smart microalgae screening and strain enhancement included) are steadily 
being developed, while carotenoid extraction methods become more efficient and 
environmentally friendly. 
x Increasing end-user awareness is apparent. The end-user numbers are constantly 
increasing with evident interest in health and sustainability-oriented lifestyles that 
encourage the development of sustainable natural carotenoids.  
x Future research (a combination of natural and synthetic production). In future 
research, there are numerous opportunities, including evolving carotenoids, new 
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applications, and innovations. The development of markets (both niche and 
commodity) will expedite the research as well. 
 
Threats 
x Stringent regulations are one of the main concerns of the industry and adaptation to 
the strict requirements undermines the rapid development of the industry.  
x Low-cost competition from Asian countries (due to lower labor and production costs 
in such labor-intensive industry) creates concerns for the western carotenoid 
markets. On the other hand, such Asian markets provide a huge number of 
consumers with inexpensive carotenoids increasing in such a way the total market. 
x Very low cost of synthetic production consists of a threat as in the laboratory it is 
hard to differentiate natural and synthetic carotenoids unless specialized techniques 
such as isotope ratio mass spectroscopy are applied (Kroll et al, 2008). Therefore, 
manufactured pigments will quickly enter the market, pretending to be falsely 
natural products. 
x The potential of contamination of biomass in an open system renders a necessity to 
manage the process with extravagant care. 
x Impact on Algae Production Due to Climatic Conditions (HTF, 2019) 
x As the process is not well-established yet it is a possible threat for any company 
entering the specific industry.  
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Table 7: A Swot analysis for microalgae-based carotenoid production companies 
Strengths Weaknesses 
x Rich diversity in terms of microalgae and 
carotenoids applicable in multiple 
markets. 
x Natural source of carotenoids. 
x Benefits from other compounds existent 
in microalgae. 
x Consumer’s awareness and enthusiasm 
for green chemistry. 
x Increased costs of production.  
x Inherent challenges of biological 
systems.  
x Downstream processing weaknesses.  
x Climate limitations for open systems. 
Opportunities Threats 
x Increase in end-user applications for 
carotenoid products and for natural 
products.  
x Improvements in cultivation and 
downstream processing.  
x Increasing end-user awareness.  
x Future research (combination of natural 
and synthetic production).  
x Stringent regulations.  
x Low-cost competition from Asian 
countries creates concerns to the 
western markets.  
x Very low cost of synthetic production. 
x Potential of contamination of biomass 
in open system. 
x Impact on Algae Production Due to 
Climatic Conditions.  
x Not yet well-estabished process poses 
threats to any incoming company. 
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6. Conclusions 
 
  The analysis of scientific data reveals that microalgae were commonly used for the 
development of different bioactive compounds as a renewable resource.  
The following development limitations could be regarded to optimize possible future 
success and restricting the limitations of microalgae biotechnology applications: 
x Therefore, it is critical to assure the quality and safety of the microalgal biomass 
and its ingredients for the consumption of human beings (as per the FDA and 
other regulatory agencies, EFSA, EMEA). On the other hand, the strict public 
European regulations for pharmaceutical and nutraceutical products delay the 
emergence of new drugs with potential health benefits. A middle way must be 
found so that regulations could be respected protecting humans without impeding 
the production of new promising medicines. 
x Research on the clinical validity of the nutraceutical and medicinal benefits of the 
bioactive products extracted from microalgae shall further enhance their 
acceptance.  
x The lack of clinical studies with humans is the main obstacle that postpones the 
significant research to proceed. In a lot of studies, the conclusion was that human 
clinical researches must be conducted in order to evaluate the scientific 
conclusions or tests on animals.  
x Many positive health effects will likely be found with increasing microalgae 
consumption as food supplements, nutraceutical, pharma, and cosmetic products. 
x Intensive bioprospecting should be pursued by the newer bioactive microalgal 
species (Nethravathy et al, 2019).  
x A comprehensive attempt should be made to evaluate the sustainability process 
through the techno-economic study, environmental efficiency, and life cycle 
assessment for the production of high-value microalgae metabolites.  
x To improve the process chain and business portfolio, the identification of the 
important factors in the manufacture, refining, storage, marketing, and 
distribution of algal products can help.  
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x A productive microalgal industry would include a biorefinery design, a zero-waste 
production strategy, and plant incorporation and intensification, meaning each 
advancement of chemical engineering, contributing to significantly reduced, 
healthier, safer, and more energy-efficient technologies.  
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7. Future perspectives 
 
  Microalgae are abundant and economically important bio-resources with various 
bioactive metabolites. A variety of microalgae species are yet to be studied. Such 
organisms require extensive scientific research to uncover their ability to benefit 
people. This will add more species to just a few existing industrial-scale microalgae. The 
food, feed, health, and cosmetic industries are covered by many high-value bioactive 
components from microalgae such as essential long-chain PUFAs (EPA, DHA), pigments, 
single-cell proteins, and mineral derived vitamines. Sustainable development and the 
growing market will likely help commercialize microalgae-based products by knowledge 
and clarity on the health of the use of microalgae and regulatory issues related to 
genetically engineered microalgae use. Research on the antibacterial activity of 
nanosized silver colloidal solutions against human pathogens has shown strong efficacy 
as a potent antimicrobial agent in the use of silver nanoparticles in drugs (Merin et al, 
2010).  
Additionally, multi–omics (genomics, transcriptomics, proteomics, and metabolomics) 
combined with data analysis have rendered biological processes easier to understand 
and require easy access to a variety of metabolic pathways for genetically modified 
microorganisms. Finally, the –omics resources will create future perspectives opening 
wider doors into microalgae research applications (Mishra et al, 2019). 
 Therefore, given the different aspects of microalgae examined, it is clear that 
microalgae with a large existence around the world will satisfy the nutrition, feed, fuel 
as well as human health needs. Marine microalgae provide a simple and effective route 
for nanoparticle syntheses with controllable, particle-sized optical properties.  
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